Peter M. Voorhees

ScholarGPS® ID: 46556864301674

Affiliation

Atrium Health, United States

Affiliation History

Field

Medicine

Discipline

Oncology

Top Specialties

Metrics Summary

Publication Count

178

Predicted Citations

7,864

Predicted h-index

Ranking

Publications and Citation History

Publications based on Top Specialties

Types of Publication

Publications
Books
Patents
NIH/NSF

Add Delete
Hereditary chronic neutrophilic leukemia in a four‐generation family without transformation to acute leukemia (journal article) Lance, Amanda \| Chiad, Zane \| Seegers, Sara L. \| Paschall, Sarah‐Catherine \| Drummond, Kendra \| Steuerwald, Nury M. \| Yang, Hsih‐Te \| Chen, Jenny \| Voorhees, Peter M. \| Avalos, Belinda R. \| Druhan, Lawrence J. American Journal of Hematology (2024). 10.1002/ajh.27420 Cite \| Source
Exposure-response analyses for optimal therapeutic dose selection of ABBV-383 in patients with relapsed/refractory multiple myeloma (RRMM). (journal article) Polepally, Akshanth \| Badillo, Jesus D \| Biesdorf de Almeida, Carla \| Voorhees, Peter M. \| D'Souza, Anita \| Kumar, Shaji \| Bueno, Orlando Felix \| Rosenberg, Tanya \| Pothacamury, Rajvineeth Kumar \| Talati, Chetasi \| ... \| Engelhardt, Benjamin Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 7541-7541 (2024). 10.1200/JCO.2024.42.16_suppl.7541 Cite \| Source
Ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma: CARTITUDE-2 cohort A expansion subgroup. (journal article) Cohen, Adam D. \| Voorhees, Peter M. \| Martin, Thomas G. \| Lesokhin, Alexander M. \| Hillengass, Jens \| Kaufman, Jonathan L. \| Schecter, Jordan Mark \| De Braganca, Kevin C. \| Varsos, Helen \| Corsale, Christina \| ... \| Einsele, Hermann Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 7535-7535 (2024). 10.1200/JCO.2024.42.16_suppl.7535 Cite \| Source
BCMA-directed CART therapy in patients with multiple myeloma and CNS involvement. (journal article) Gaballa, Mahmoud R. \| Castaneda Puglianini, Omar Alexis \| Cohen, Adam D. \| Vogl, Dan T. \| Chung, Alfred \| Ferreri, Christopher J. \| Voorhees, Peter M. \| Hansen, Doris K. \| Patel, Krina K. Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 7519-7519 (2024). 10.1200/JCO.2024.42.16_suppl.7519 Cite \| Source
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study (journal article) Nooka, Ajay K. \| Kaufman, Jonathan L. \| Rodriguez, Cesar \| Jakubowiak, Andrzej \| Efebera, Yvonne \| Reeves, Brandi \| Wildes, Tanya M. \| Holstein, Sarah A. \| Anderson, Larry D. \| Badros, Ashraf \| ... \| Richardson, Paul G. British Journal of Haematology, volume 204, issue 6, pages 2227-2232 (2024). 10.1111/bjh.19386 Cite \| Source
Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study) (journal article) Ehsan, Hamid \| Robinson, Myra \| Voorhees, Peter M. \| Cassetta, Kristen \| Borden, Shanice \| Atrash, Shebli \| Bhutani, Manisha \| Varga, Cindy \| Pineda-Roman, Mauricio \| Friend, Reed \| Paul, Barry A. Life, volume 14, issue 3, pages 384- (2024). 10.3390/life14030384 Cite \| Source
Acquired Immunity in Patients with Multiple Myeloma Undergoing Maintenance Therapy Post-Autologous Hematopoietic Cell Transplantation (journal article) Plesca, Dragos C. \| Foureau, David M \| Symanowski, James T. \| Druhan, Lawrence \| Hill, Hailey \| Karabinos, Allison \| McElwee, Jessica \| Elsey, Grace \| Morse, Allison \| Cook, Allene \| ... \| Voorhees, Peter M. Transplantation and Cellular Therapy, volume 30, issue 2, pages S455- (2024). 10.1016/j.jtct.2023.12.660 Cite \| Source
Idecabtagene Vicleucel (ide-cel) Chimeric Antigen Receptor T-Cell for Plasma Cell Leukemia (PCL): A Multicenter Experience (journal article) Fortuna, Gliceida Maria Galarza \| Sidana, Surbhi \| Hovanky, Vanna \| Khouri, Jack \| Dima, Danai \| Kocoglu, Mehmet H. \| Forsberg, Peter \| Ferreri, Christopher \| Atrash, Shebli \| Voorhees, Peter M. \| ... \| Sborov, Douglas Transplantation and Cellular Therapy, volume 30, issue 2, pages S381-S382 (2024). 10.1016/j.jtct.2023.12.534 Cite \| Source
Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide(Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Real World Experience (journal article) Varga, Cindy \| Robinson, Myra \| Ehsan, Hamid \| Roberts, Danielle \| Dicamillo, Sara \| Gupta, Vikas \| Borden, Shanice \| Bhutani, Manisha \| Paul, Barry A. \| Atrash, Shebli \| ... \| Joseph, Nisha Transplantation and Cellular Therapy, volume 30, issue 2, pages S377-S378 (2024). 10.1016/j.jtct.2023.12.528 Cite \| Source
Assessment of Incidence of Distress and Utilization of Supportive Care Services in Multiple Myeloma Patients, a Retrospective Single Center Experience (journal article) Ehsan, Hamid \| Robinson, Myra \| Meadors, Patrick \| Patel, Rushil \| Borden, Shanice \| Voorhees, Peter M. \| Walsh, Delcan \| Paul, Barry \| Bhutani, Manisha \| Varga, Cindy \| Atrash, Shebli Blood, volume 142, issue Supplement 1, pages 7416-7416 (2023). 10.1182/blood-2023-178114 Cite \| Source
Pharmacokinetics and Immunogenicity of Abbv-383, a B-Cell Maturation Antigen (BCMA) × CD3 Bispecific T-Cell-Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) (journal article) Polepally, Akshanth R \| Biesdorf, Carla \| Uddin, Muhammad Erfan \| Boehm, Nils \| Ross, Jeremy A \| Kumar, Shaji Kunnathu \| Voorhees, Peter M. \| D'Souza, Anita \| Weisel, Katja \| Bueno, Orlando \| ... \| Menon, Rajeev M Blood, volume 142, issue Supplement 1, pages 6722-6722 (2023). 10.1182/blood-2023-180127 Cite \| Source
Serum Proteomic Profiling to Identify Biomarkers of Progression from Monoclonal Gammopathy of Unknown Significance (MGUS) to Multiple Myeloma (MM) Among African Americans and Whites (journal article) Varga, Cindy \| Zimmerman, Kip \| Foureau, David \| Nazli, Sumaiya A \| Voorhees, Peter M. \| Olivier, Michael \| Bhutani, Manisha Blood, volume 142, issue Supplement 1, pages 6597-6597 (2023). 10.1182/blood-2023-179385 Cite \| Source
Primary Endpoint Analysis from a Response Adaptive Phase II Clinical Trial of Carfilzomib, Lenalidomide, Dexamethasone Plus Daratumumab (KRd-Dara) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) (journal article) Bhutani, Manisha \| Robinson, Myra \| Atrash, Shebli \| Paul, Barry \| Pineda-Roman, Mauricio \| Foureau, David \| Varga, Cindy \| Friend, Reed \| Begic, Xhevahire \| Norek, Sarah \| ... \| Usmani, Saad Z Blood, volume 142, issue Supplement 1, pages 3380-3380 (2023). 10.1182/blood-2023-174972 Cited by (1) \| Cite \| Source
Venetoclax in Combination with Daratumumab and Dexamethasone Elicits Deep, Durable Responses in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma: Updated Analyses of Minimal Residual Disease Negativity in Phase 1/2 Study (journal article) Bahlis, Nizar J \| Quach, Hang \| Baz, Rachid \| Vangsted, Annette J. \| Ho, Shir-Jing \| Abildgaard, Niels \| Laubach, Jacob \| Ribrag, Vincent \| Voorhees, Peter M. \| Wang, Xifeng \| ... \| Kaufman, Jonathan L. Blood, volume 142, issue Supplement 1, pages 338-338 (2023). 10.1182/blood-2023-180766 Cited by (1) \| Cite \| Source
Efficacy and Safety of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM): Final Analysis of the Phase 2 Centaurus Study (journal article) Landgren, Ola \| Chari, Ajai \| Cohen, Yael C. \| Spencer, Andrew \| Voorhees, Peter M. \| Sandhu, Irwindeep \| Jenner, Matthew W. \| Smith, Dean \| Cavo, Michele \| van de Donk, Niels WCJ \| ... \| Hofmeister, Craig C. Blood, volume 142, issue Supplement 1, pages 210-210 (2023). 10.1182/blood-2023-181765 Cited by (4) \| Cite \| Source
Patterns of Outpatient IVIG Use before and during the COVID Pandemic in Patients with Multiple Myeloma (journal article) Lambird, Jonathan \| Mckay, John T \| Lin, Meng-Yun \| Abdelfattah, Lindsey \| Bhutani, Manisha \| Paul, Barry \| Voorhees, Peter M. \| Varga, Cindy \| Atrash, Shebli \| Hurd, David Duane Blood, volume 142, issue Supplement 1, pages 6634-6634 (2023). 10.1182/blood-2023-180345 Cite \| Source
Rural-Urban and Racial Trends in Survival of Patients with Multiple Myeloma: 1975-2019 Surveillance, Epidemiology, and End Results (SEER) Analysis (journal article) Testamark, Semaje \| Verbyla, Allison \| Robinson, Myra \| Voorhees, Peter M. \| Bhutani, Manisha Blood, volume 142, issue Supplement 1, pages 1977-1977 (2023). 10.1182/blood-2023-175032 Cite \| Source
Bone marrow Ki‐67 index is of prognostic value in newly diagnosed multiple myeloma (journal article) Atrash, Shebli \| Robinson, Myra \| Taneja, Alankrita \| Paul, Barry \| Cassetta, Kristen \| Ndiaye, Ami \| Varga, Cindy \| Block, Jared \| Lipford, Edward H. \| Smith, Elton T. \| ... \| Bhutani, Manisha European Journal of Haematology, volume 111, issue 3, pages 373-381 (2023). 10.1111/ejh.14016 Cited by (1) \| Cite \| Source
P-277 Venetoclax versus bortezomib, in combination with daratumumab and dexamethasone, in patients with t(11;14)-positive relapsed or refractory multiple myeloma (journal article) Kaufman, Jonathan \| Quach, Hang \| Baz, Rachid \| Vangsted, Annette Juul \| Ho, Shir-Jing \| Abildgaard, Niels \| Laubach, Jacob \| Ribrag, Vincent \| Gibbs, Simon \| Medvedova, Eva \| ... \| Bahlis, Nizar Clinical Lymphoma Myeloma and Leukemia, volume 23 (2023). 10.1016/S2152-2650(23)01895-5 Cite \| Source
P-226 Safety and clinical activity of belantamab mafodotin combined with carfilzomib, lenalidomide, and dexamethasone after at least one prior line of therapy, interim results from phase 1 clinical trial (journal article) Atrash, Shebli \| Symanowski, James \| Paul, Barry \| Varga, Cindy \| Begic, Xhevahire \| Norek, Sarah \| Bhutani, Manisha \| Voorhees, Peter Clinical Lymphoma Myeloma and Leukemia, volume 23 (2023). 10.1016/S2152-2650(23)01844-X Cite \| Source

Title	Investigators	Year	Cost	Agency
PROTOCOL REVIEW AND MONITORING SYSTEM (Core 019)	Voorhees, Peter	2020	$143,396	NATIONAL CANCER INSTITUTE
PROTOCOL REVIEW AND MONITORING SYSTEM (Core 019)	Voorhees, Peter	2019	$138,994	NATIONAL CANCER INSTITUTE
PROTOCOL REVIEW AND MONITORING SYSTEM (Core 019)	Voorhees, Peter	2018	$143,392	NATIONAL CANCER INSTITUTE
PROTOCOL REVIEW AND MONITORING SYSTEM (Core 019)	Voorhees, Peter	2018	$2,102	NATIONAL CANCER INSTITUTE
PROTOCOL REVIEW AND MONITORING SYSTEM (Core 019)	Voorhees, Peter	2018	$1,366	NATIONAL CANCER INSTITUTE
PROTOCOL REVIEW AND MONITORING SYSTEM (Core 019)	Voorhees, Peter	2018	$2,968	NATIONAL CANCER INSTITUTE
PROTOCOL REVIEW AND MONITORING SYSTEM (Core 019)	Voorhees, Peter	2017	$140,677	NATIONAL CANCER INSTITUTE
PROTOCOL REVIEW AND MONITORING SYSTEM (Core 019)	Voorhees, Peter	2016	$141,520	NATIONAL CANCER INSTITUTE
CLINICAL TRIAL: PX-171-001-PHASE I STUDY OF ESCALATING DOSES OF PROTEASOME INHIB	Voorhees, Peter	2008	$4,209	NATIONAL CENTER FOR RESEARCH RESOURCES
LCCC 0406: ADDITION OF CELLCEPT TO GLEEVEC IN THE TREATMENT OF LEUKEMIA	Voorhees, Peter	2007	$187	NATIONAL CENTER FOR RESEARCH RESOURCES
LCCC 0406: ADDITION OF CELLCEPT TO GLEEVEC IN THE TREATMENT OF LEUKEMIA	Voorhees, Peter	2006	$3,964	NATIONAL CENTER FOR RESEARCH RESOURCES